Cargando…

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells

Background: Upregulation of anti-apoptotic Bcl-2 proteins in advanced prostate cancer leads to therapeutic resistance by prevention of cell death. New therapeutic approaches aim to target the Bcl-2 proteins for the restoration of apoptosis. Methods: The immunotoxin hD7-1(VL-VH)-PE40 specifically bin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masilamani, Anie P., Dettmer-Monaco, Viviane, Monaco, Gianni, Cathomen, Toni, Kuckuck, Irina, Schultze-Seemann, Susanne, Huber, Nathalie, Wolf, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352695/ https://www.ncbi.nlm.nih.gov/pubmed/32580291 http://dx.doi.org/10.3390/cancers12061648

Ejemplares similares

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2011)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
por: Baev, Denis V., et al.
Publicado: (2014)

Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861
por: Masilamani, Anie P., et al.
Publicado: (2023)

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine
por: Stamelos, Vasileios A, et al.
Publicado: (2012)

The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
por: Broecker-Preuss, Martina, et al.
Publicado: (2016)

By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737
por: Tailler, Maximilien, et al.
Publicado: (2018)

Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma
por: Risberg, Karianne, et al.
Publicado: (2011)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer
por: Shin, Ji-Ae, et al.
Publicado: (2015)

The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53
por: Reuland, Steven N., et al.
Publicado: (2011)

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
por: Séveno, Céline, et al.
Publicado: (2012)

Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737
por: Maamer-Azzabi, A, et al.
Publicado: (2013)

Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis
por: Yamaguchi, R, et al.
Publicado: (2011)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2014)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2015)

A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML
por: Wang, Qing, et al.
Publicado: (2019)

Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells
por: Pandey, Manoj K., et al.
Publicado: (2013)

ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model
por: Lee, Jung Mo, et al.
Publicado: (2022)

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
por: Nakajima, W, et al.
Publicado: (2014)

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011)

Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016)

Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression
por: Woo, S M, et al.
Publicado: (2014)

RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway
por: Keuling, Angela M., et al.
Publicado: (2009)

Use of Human Cancer Cell Lines Mitochondria to Explore the Mechanisms of BH3 Peptides and ABT-737-Induced Mitochondrial Membrane Permeabilization
por: Buron, Nelly, et al.
Publicado: (2010)

In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer
por: Michalska, Marta, et al.
Publicado: (2016)

Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells
por: Adamová, Barbora, et al.
Publicado: (2022)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
por: Rubio-Patiño, Camila, et al.
Publicado: (2016)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019)

Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737
por: Shahverdi, Mahshid, et al.
Publicado: (2020)

Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
por: Yamaguchi, Ryuji, et al.
Publicado: (2011)

Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC
por: Gilormini, Marion, et al.
Publicado: (2016)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
por: Lomovsky, Alexey, et al.
Publicado: (2020)

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5fmoqifkm2j76rk3unkai11v1o